이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

무선 캡슐을 사용하여 위산 배출량을 결정하는 새로운 방법

Background:

- Acid-related gastrointestinal disorders are numerous and may require chronic treatment and maintenance, but they are often difficult to diagnose and treat. Gastric analysis is a critical tool for diagnosing and treating acid-related disorders; however, at present it requires a technically difficult procedure, using a nasogastric tube, that is costly, invasive, and uncomfortable. Recently a new tool, the SmartPill, has been developed that can measure acid levels, temperature, and pressure throughout the stomach, small intestine, and colon by swallowing a small capsule. Researchers are interested in comparing current methods of measuring stomach acid with the SmartPill by studying both healthy volunteers and individuals with acid-related gastrointestinal disorders.

Objectives:

- To evaluate the usefulness and accuracy of the SmartPill for gastric analysis, compared with current procedures.

Eligibility:

  • Phase 1A/1B: Healthy volunteers between 18 and 60 years of age.
  • Phase 2: Individuals at least 18 years of age who have been diagnosed with Zollinger-Ellison Syndrome or acid hypersecretion.
  • Phase 3: Individuals at least 18 years of age who have been diagnosed with refractory gastroesophageal reflux disease, peptic ulcer disease, or idiopathic gastric hypersecretion.

Design:

  • This study involves a screening visit, a 3-day inpatient study visit, and possible additional outpatient visits.
  • Participants will be screened with a medical history and physical examination, as well as blood and urine samples.
  • Phase 1A/1B: Participants will have a 3-day inpatient study visit with the following procedures:
  • Imaging study of the stomach (simultaneous gastric emptying scintigraphy), followed by a special diet for the next day s test.
  • Gastric analysis using a nasogastric tube to collect stomach acid secretions.
  • SmartPill study, in which participants will ingest a SmartPill and wear a monitor for 24 to 48 hours to collect readings.
  • Participants in Phase 1A will have a second outpatient SmartPill study 7 days after the first SmartPill study. Participants in Phase 1B will not have the second SmartPill study.
  • Phase 2 and Phase 3: Participants will have a 3-day inpatient study visit with the following procedures:
  • Imaging study of the stomach (simultaneous gastric emptying scintigraphy), followed by a special diet for the next day s test.
  • Gastric analysis using a nasogastric tube to collect stomach acid secretions.
  • SmartPill study, in which participants will ingest a SmartPill and wear a monitor for 24 to 48 hours to collect readings.
  • Phase 2 and 3 participants will have outpatient study visits only if directed by the study researchers.

연구 개요

상세 설명

Acid related disorders are numerous and often require chronic treatment and maintenance. Many of these diseases are without symptoms and therefore difficult to diagnose and treat. Gastric analysis is the quantitative measurement of gastric acid output and is a critical tool for the diagnosis of acid related disorders and the ongoing assessment of therapy response. At present gastric analysis requires a technically difficult procedure, using gastric aspiration through a nasogastric tube, that is costly, invasive, and uncomfortable for patients. Recently there is introduction of the SmartPill, which is a disposable pill that measures pH, temperature, and pressure throughout the GI tract. We propose a pilot study to validate a new method of gastric analysis with the ingestion of the SmartPill with a meal of a known buffering capacity to measure both the acidity and quantity of acid output in the stomach. We will validate this method by comparing it to the accepted gastric aspiration method under maximally stimulated conditions. We will study healthy volunteers for the validation phase and then study patients with known acid related disorders to assess its usefulness in patients. Interested subjects will report to the NIH outpatient gastrointestinal clinic for evaluation to be followed by a 3 day in-patient admission and 2 subsequent clinic visits. Subjects will have gastric analysis of basal, meal stimulated, and pharmacologically stimulated rates with both the conventional and study methods. Outcomes will include a quantitative measurement of gastric acid output in unit time, normal meal stimulated acid output values in healthy volunteers and patients with acid related disorders, and the assessment of acid suppression in patients treated with a variety of anti-secretory medications.

연구 유형

관찰

등록 (실제)

80

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • National Institutes of Health Clinical Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Healthy volunteers and patients with gastric acid secretory disorders

설명

  • CURRENTLY ONLY RECRUITING Patients with Zollinger Ellison Syndrome and Hypersecretion AND Patients with Refractory GERD, Peptic ulcer disease, Idiopathic Gastric Hypersecretion

Phase II, Use in Patients with Zollinger Ellison Syndrome and Hypersecretion

INCLUSION:

  • Zollinger-Ellison syndrome (ZES) as diagnosed by one of the following criteria: histologic confirmation of gastrinoma, positive provocative testing with secretin (an increase of >200 pg/mL postinjection), gastric acid hypersecretion (BAO > 15) in the presence of hypergastrinemia (fasting serum gastrin > 99)
  • Multiple endocrine neoplasia type-I (MEN1) with suspicion of ZES (hypergastrinemia) undergoing evaluation. MEN-I with ZES
  • Hypergastrinemia (serum gastrin > 99)

Patients must meet at least 1 of the above inclusion criteria and the following:

  • Ages equal to or greater than 18 years
  • Male, females, all ethnicities

EXCLUSION:

  • History of gastric surgery (gastrectomy, pyloroplasty)
  • Use of bowel motility medications such as, but not limited to, Reglan, Immodium, and Lomotil
  • Contraindication to SmartPill: history of gastric bezoar, disorders of swallowing, suspected strictures, fistulas, or physiological GI obstruction, GI surgery within the past three months, severe dysphagia to food or pills, Crohn s Disease or diverticulitis, a subject who uses an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump
  • Pregnancy and breastfeeding. Females of childbearing potential must be on an acceptable means of birth control and no intercourse in 2 weeks prior to study enrollment.
  • Lactose intolerance or inability to drink standard meal of Ensure Plus
  • Estabished diagnosis of gastroparesis
  • Significant systemic or major illnesses including, but not limited to, stroke, congestive heart failure, renal failure (creatinine clearance < 50 ml/min), organ transplantation, angina pectoris, active malignancy, and autonomic neuropathy
  • Unstable psychiatric conditions, untreated or uncontrolled depression or generalized anxiety disorder, substance abuse within the past year, in order to prevent feeling of being uncomfortable or to prevent lack of follow-up
  • Use of not-steroidal anti-inflammatory drugs for 2 weeks prior to study enrollment

Phase IIIA, Use in Patients with Refractory GERD, Peptic ulcer disease, Idiopathic Gastric Hypersecretion

INCLUSION:

  • Gastric acid hypersecretion (BAO>15 mEq/hr)
  • Conditions with gastric acid hypersecretion including, but not limited to, patients with systemic mastocytosis (SM)
  • Refractory GERD (patients with persistant symptoms despite being on standard medical therapy), PUD, and suspected idiopathic gastric hypersecretion

Patients must meet at least 1 of the above inclusion criteria and the following:

  • Ages equal to or greater than 18 years
  • Male, females, all ethnicities

EXCLUSION:

  • History of gastric surgery (gastrectomy, pyloroplasty).
  • Use of bowel motility medications such as, but not limited to, Reglan, Immodium, and Lomotil
  • Contraindication to SmartPill: history of gastric bezoar, disorders of swallowing, suspected strictures, fistulas, or physiological GI obstruction, GI surgery within the past three months, severe dysphagia to food or pills, Crohn s Disease or diverticulitis, a subject who uses an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump
  • Pregnancy and breastfeeding. Females of childbearing potential must be on an acceptable means of birth control and no intercourse in 2 weeks prior to study enrollment.
  • Lactose intolerance or inability to drink standard meal of Ensure Plus
  • Established diagnosis of gastroparesis
  • Significant systemic or major illnesses including, but not limited to, stroke, congestive heart failure, renal failure (creatinine clearance < 50 ml/min), organ transplantation, angina pectoris, active malignancy, and autonomic neuropathy
  • Unstable psychiatric conditions, untreated or uncontrolled depression or generalized anxiety disorders, substance abuse within the past year, in order to prevent feeling of being uncomfortable or to prevent lack of follow-up. Use of non-steroidal anti-inflammatory drugs for 2 weeks prior to study enrollment.

Phase IIIB, Use in Patients with Medication-Controlled: GERD, Peptic ulcer disease, Idiopathic Gastric Hypersecretion

INCLUSION:

-Medication-controlled (patients whose symptoms resolve with medication):GERD, PUD, and suspected idiopathic gastric hypersecretion

Patients must meet the above inclusion criteria and the following

  • Ages equal to or greater than 18 years
  • Male, females, all ethnicities

EXCLUSION:

  • Refractory to medication: GERD (patients with persistant symptoms despite being on standard medical therapy), PUD, and suspected idiopathic gastric hypersecretion
  • History of gastric surgery (gastrectomy, pyloroplasty).
  • Use of bowel motility medications such as, but not limited to, Reglan, Immodium, and Lomotil
  • Contraindication to SmartPill: history of gastric bezoar, disorders of swallowing, suspected strictures, fistulas, or physiological GI obstruction, GI surgery within the past three months, severe dysphagia to food or pills, Crohn s Disease or diverticulitis, a subject who uses an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump
  • Pregnancy and breastfeeding. Females of childbearing potential must be on an acceptable means of birth control and no intercourse in 2 weeks prior to study enrollment.
  • Lactose intolerance or inability to drink standard meal of Ensure Plus
  • Established diagnosis of gastroparesis
  • Significant systemic or major illnesses including, but not limited to, stroke, congestive heart failure, renal failure (creatinine clearance < 50 ml/min), organ transplantation, angina pectoris, active malignancy, and autonomic neuropathy
  • Unstable psychiatric conditions, untreated or uncontrolled depression or genralized anxiety disorders, substance abuse within the past year, in order to prevent feeling of being uncomfortable or to prevent lack of follow-up
  • Use of non-steroidal anti-inflammatory drugs for 2 weeks prior to study enrollment

RECRUITMENT IS CLOSED FOR Phase IA/IB, Validation and Establishment of Nomogram in Healthy Volunteers

PHASE IA/IB INCLUSION:

  • Healthy volunteers
  • Ages 18-60
  • Males, females, all ethnicities

PHASE IA/IB EXCLUSION:

  • History of gastric or bowel surgery
  • Use of bowel motility medications such as, but not limited to, Reglan, Immodium, and Lomotil
  • Use of antacid, antisecretory, and anticholinergic medications such as, but not limited to, proton pump inhibitors and histamine 2 receptor antagonists
  • Use of non-steroidal anti-inflammatory drugs for 2 weeks prior to study enrollment
  • Hypersecretory and hyposecretory related conditions including, but not limited to, pernicious anemia, atrophic gastritis, and Zollinger-Ellison syndrome
  • Contraindication to NGT: deviated septum, history of transphenoidal surgery, chronic sinusitis, severe facial trauma (cribriform plate disruption, sustained head trauma, maxillofacial injury, or anterior fossa skull fracture), esophageal stricture, esophageal varices, altered mental status, and impaired airway
  • Contraindication to scintigraphy: allergy to sulfa-colloid
  • Contraindication to pentagastrin: allergy to pentagastrin, active gastrointestinal bleeding, active peptic ulcer disease, active gallbladder and liver disease, pancreatitis, and bowel obstruction
  • Contraindication to SmartPill: history of gastric bezoar, disorders of swallowing, suspected strictures, fistulas, or physiological GI obstruction, GI surgery within the past three months, severe dysphagia to food or pills, Crohns disease or diverticulosis, and implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump
  • Pregnancy and breastfeeding. Females of childbearing potential must be on an acceptable means of birth control and no intercourse in 2 weeks prior to study enrollment.
  • Lactose intolerance or inability to drink standard meal of Ensure Plus
  • Helicobacter pylori infection
  • Gastroparesis
  • History of gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, or inflammatory bowel disease
  • Significant systemic or major illnesses including, but not limited to, stroke, cardiovascular disease, hypertension, congestive heart failure, renal failure (creatinine clearance < 50 ml/min), organ transplantation, angina pectoris, active malignancy, diabetes, or autonomic neuropathy
  • Unstable psychiatric conditions, depression, generalized anxiety disorder, or substance abuse within the past year, in order to prevent feeling of being uncomfortable or to prevent lack of follow-up

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: CASE_CONTROL
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Healthy volunteers

Healthy volunteers between 18 and 60 years of age

patients with gastric acid secretory disorders

18 years of age who have been diagnosed with Zollinger-Ellison Syndrome or acid hypersecretion.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
examines the safety and efficacy of disposable, wireless capsule (SmartPill)
기간: until protocol closes

This study examines the safety and efficacy of disposable, wireless capsule (SmartPill) devices in determining gastric acid output in comparison to current standard gastric aspiration procedures, which are more invasive and inconvenient.

until protocol closes

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Stephen A Wank, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2008년 6월 18일

연구 등록 날짜

최초 제출

2008년 6월 19일

QC 기준을 충족하는 최초 제출

2008년 6월 19일

처음 게시됨 (추정된)

2008년 6월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 10월 16일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다